NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

pgsd, Here's some comments from Dr. Andrew that point to how much reembursement NWBO might get under these changes taken effect this month in the UK:

Andrew Caravello, DO
@andrewcaravello
·
6h
NICE CEO Professor Jonathan Benger confirmed on April 2, 2026 that the new cost-effectiveness thresholds (£25,000-£35,000/QALY) apply immediately to both new and ongoing medicines evaluations. NICE ID836 ( $NWBO #DCVax-L for glioblastoma) is an ongoing evaluation. Combined with the severity modifier for #GBM’s extreme disease burden, the effective willingness-to-pay ceiling for DCVax-L’s NICE appraisal is now £42,000-£59,500 per QALY. The old thresholds are gone. The new ones apply the moment the committee sits.